Tag Archives: Abbott

ADA 2026 Key Press Releases (June 6)

On the second day of the ADA 2026 conference, nine cardiometabolic-related news items have been observed from Pfizer, Abbott, Novo Nordisk, Hengrui/Kailera Therapeutics, Insulet, Dexcom, MannKind, Biomea Fusion, and Tidepool. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Already a member? Log in here

MiniMed FY Q1 ’26 Earnings; Insulet Enhances O5 Algorithm and Integrates with Libre 3 Plus CGM; myLoop AID and Dexcom G7 CGM Integration Launches in EU

Three cardiometabolic-related news items have been observed: MiniMed hosted its CY Q1 ‘26 (FY Q4 ’26) earnings call (view press release; view slides); Insulet rolled out an updated O5 algorithm and expanded integration with Libre 3 Plus CGM (view press release); and CamDiab’s myLoop AID + Dexcom G7  CGM integration launched in the EU (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

ADA 2026 Preview: Where FENIX will be paying close attention and why

With ADA 2026 approaching (June 5-8; New Orleans, LA), FENIX has compiled a shortlist of key sessions and presentations that warrant close attention across the meeting. While ADA brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately, have an outsized impact on the field for years to come.

This content is for Read Less members only.
Already a member? Log in here

Pfizer’s Andrew Baum to Depart at the End of 2026; Amazon Launches AOM Management Program; Dexcom Opens First OUS CGM Manufacturing Site; Kailera Closes IPO; BioAge Reports Additional Ph1 NLRP3i Data; Abbott Wins Preliminary Injunction Appeal Against Sinocare

A series of cardiometabolic-related news items has been observed from Pfizer, Amazon, Dexcom, Kailera Therapeutics, BioAge Labs, and Abbott. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

ATTD 2026 Key Press Releases (March 12)

On the second day of ATTD 2026, three cardiometabolic-related news items have been observed: Lilly issued a public warning letter regarding the risk of compounded tirzepatide (view press release); Breakthrough T1D released a statement on cadaver donor islet cells and the ISLET Act (view press release); and Abbott shared results from its FreeDM2 study comparing Libre vs. SMBG in T2DM basal patients (view press release). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Hims Launches Compounded Sema Pill; Novo London, AbbVie, GSK, and Novartis Q4 ’25 Earnings; Stelo Smart Meal Logging Updates; Abbott FDA Warning Letter and Class I Recall; Rare Pediatric PRV Program Reauthorized; Sciwind Ph3 OSA Study

A series of cardiometabolic-related news items has been observed from Hims & Hers, Novo Nordisk, AbbVie, GSK, Novartis, Dexcom, Abbott, the White House, and Sciwind Biosciences. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Novo Initiates Two Cagrisema Formulation/Device Trials; Lilly Initiates Third Ph3 Eloralintide Trial; FDA Approves Zepbound Kwikpen; Roche Increases Investment for Obesity Manufacturing Site; Abbott Q4 ’25 Earnings; CORXEL Closes $287M Series D1 Funding; Sesame Partners with Novo for Wegovy Pill

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Lilly, Roche, Abbott, Corxel Pharmaceuticals, and Sesame. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here